Translational Neurodegeneration

Papers
(The TQCC of Translational Neurodegeneration is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes890
Current understanding of metal ions in the pathogenesis of Alzheimer’s disease214
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential122
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration120
The emerging roles of vacuolar-type ATPase-dependent Lysosomal acidification in neurodegenerative diseases90
Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives81
Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments78
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond78
COVID-19 and Alzheimer’s disease: how one crisis worsens the other72
Advances in the development of new biomarkers for Alzheimer’s disease68
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases66
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases62
Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation57
The compensatory phenomenon of the functional connectome related to pathological biomarkers in individuals with subjective cognitive decline47
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review47
Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study46
Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy44
TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut42
Human iPSCs derived astrocytes rescue rotenone-induced mitochondrial dysfunction and dopaminergic neurodegeneration in vitro by donating functional mitochondria41
The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson’s disease40
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease39
A new paradigm for diagnosis of neurodegenerative diseases: peripheral exosomes of brain origin39
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis39
Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease38
Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies38
Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer’s dementia37
Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer’s disease37
Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications37
Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer’s disease36
Upregulation of RIN3 induces endosomal dysfunction in Alzheimer’s disease36
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases36
Maintaining the balance of TDP-43, mitochondria, and autophagy: a promising therapeutic strategy for neurodegenerative diseases33
CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers32
Transplantation of bone marrow mesenchymal stem cells improves cognitive deficits and alleviates neuropathology in animal models of Alzheimer’s disease: a meta-analytic review on potential mechanisms32
Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation31
SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease31
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?30
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia30
Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration30
GCH1 variants contribute to the risk and earlier age-at-onset of Parkinson’s disease: a two-cohort case-control study30
Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal29
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis26
Mitochondrial links between brain aging and Alzheimer’s disease25
Parkinson’s disease–associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy25
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms25
The effects of transcranial direct current stimulation on gait in patients with Parkinson’s disease: a systematic review25
An old weapon with a new function: PIWI-interacting RNAs in neurodegenerative diseases25
Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases25
Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis?24
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease23
Exploring the regulatory roles of circular RNAs in Alzheimer’s disease22
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease22
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance22
Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients21
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock21
The emerging role of furin in neurodegenerative and neuropsychiatric diseases21
Circadian disruption and sleep disorders in neurodegeneration21
Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers21
Prodromal Parkinson's disease: hype or hope for disease-modification trials?21
Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis21
0.071502923965454